.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Mallinckrodt
McKesson
Baxter
Teva
Moodys
McKinsey
Accenture
Covington
Express Scripts

Generated: June 28, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,915,247

« Back to Dashboard

Claims for Patent: 7,915,247

Title:Methods of use of fenofibric acid
Abstract:Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Inventor(s): Arnold; Kristin Anne (Morrisville, PA), Feng; Hengsheng (Cherry Hill, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:12/141,280
Patent Claims: 1. A method of treating a human patient in need of treatment for primary hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, or mixed hyperlipidemia, comprising orally administering to the patient once daily an immediate-release 105 mg fenofibric acid dosage form, wherein the dosage form comprises 1 wt % to 30 wt % of a disintegrant, 30 wt % to 90 wt % of a filler, 0.1 wt % to 20 wt % of a binder, and 0.01 wt % to 10 wt % of a lubricant, and wherein the dosage form does not include an enteric binder and does not include a surfactant, wherein the 105 mg fenofibric acid dosage form is bioequivalent to a 145 mg fenofibrate dosage form under fasted and standard or low-fat meal non-fasted conditions, wherein the fenofibrate dosage form comprises particles of fenofibrate having an effective average particle size of less than about 2000 nm and having associated with the surface thereof a surface stabilizer comprising hypromellose, sodium lauryl sulfate and dioctyl sodium sulfosuccinate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Teva
McKinsey
Fuji
Cipla
Boehringer Ingelheim
Citi
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot